Approximate duration of enrollment: 18 months~Total study duration: approximately 3 years~This is a national, multicenter observational retrospective and prospective cohort data collection study. Retrospective is defined as collection of data from all patients, including deceased patients, who were already on early access olipudase alfa in France before the start of this study.
Primary Objective:~To describe the lung, spleen and liver outcomes of olipudase alfa~Secondary Objectives:~To describe the patient's characteristics~To describe conditions of olipudase alfa use~To describe safety data related to the use of olipudase alfa~To describe complementary effectiveness outcomes parameters